Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
51 matching companiesShowing 1–24 / 51
Offers RNA synthesis, LNP / tLNP formulation screening, analytical characterization, and early-stage manufacturing. The website describes manufacturing as GMP-like for preclinical, toxicology, and IND-enabling programs; this should not be equated with full cGMP commercial manufacturing.
WuXi STA's injectable drug product platform lists mRNA/DNA-LNP and end-to-end LNP services, including lipid discovery, formulation and process development, analysis, and manufacturing.
A publicly traded mRNA drug company with a disclosed platform spanning mRNA design, LNP delivery, and drug substance and drug product manufacturing.
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
Develops the LUNAR lipid delivery and STARR self-amplifying mRNA platforms. KOSTAIVE is an approved sa-mRNA COVID-19 vaccine.
Active in nucleic acid synthesis since 1996; a Maravai-owned CDMO supplying mRNA, NTPs, and CleanCap capping reagents.
Founded in 2009, this LNP delivery technology company advances nucleic acid drug delivery R&D and commercialization primarily through partners. Licensed platforms are not classified as company-owned drug candidates.
Public service pages disclose mRNA/saRNA analysis, including IPRP-HPLC, RT-qPCR, cell-free potency assays, and LNP characterization. These disclosures do not establish full mRNA-LNP manufacturing at every site.
Offers mRNA/LNP process and analytical development and clinical and small-scale commercial manufacturing. Geleen integrates RNA and LNP production.
Evonik combines its lipid/LNP development services with ST PHARM's custom nucleic acid capabilities. A partnered supply chain does not mean Evonik manufactures every component itself.
BioNTech announced completion of its CureVac acquisition on 2025-12-18. This record retains CureVac's mRNA technology and historical entity information without treating it as an independent publicly traded company.
Uses mRNA technology to develop respiratory treatments; official disclosures report 2022 financing and a strategic investment from Cipla.
Offers mRNA engineering, custom LNPs, and manufacturing technology platforms to support partners from design through production.
Discloses an integrated mRNA/LNP platform. Its lyophilized shingles mRNA vaccine ABO1108 is in Phase 3 in China. The ABO2203 licensing and option agreement with Novartis announced on 2026-10-02 is not classified as financing.
Founded in July 2021, the company focuses on innovative mRNA drugs and adjuvants, with oncology, infectious disease, and other mRNA programs.
Founded in 2019, the company discloses mRNA molecular engineering, delivery, and immunomodulation platforms with CMC integrated into technology development.
IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
Develops gene delivery platforms for mRNA, saRNA, siRNA, and ASOs, along with internal drug programs. In 2026 it announced an LNP platform and Korean-market collaboration with Crystal NAX.
Develops mRNA and gene correction therapies using tissue-selective LNP delivery. In 2026 it disclosed additional Cystic Fibrosis Foundation support and a cystic fibrosis gene-editing collaboration.
Develops mRNA cell therapies, with a lead program based on ex vivo mRNA CAR-T. It also collaborates with WestGene on in vivo tLNP delivery; these approaches should be evaluated separately.
A clinical-stage self-replicating RNA technology developer spanning infectious diseases, immunology, and other therapeutic areas.
Develops RNA nanodelivery through a non-lipid approach adjacent to LNP technology; it should not be classified as a conventional LNP platform.
Founded in 2019, the company develops self-amplifying RNA vaccines and therapeutics and LNP platforms.
Offers RNA drug substance, LNP encapsulation, analytical testing, and aseptic fill-finish, with disclosed mRNA-LNP manufacturing in one facility under one quality system.
Coverage expands from sourced records; this database does not claim all biopharma companies.
